Results 191 to 200 of about 57,189 (285)

Targeting chordoma via an isocitrate dehydrogenase-1-dependent susceptibility to redox metabolism. [PDF]

Acta Neuropathol
Pun M, Deogharkar A, Natarajan SK, Nuechterlein N, Tian W, Ji S, Young E, Yang F, Hawes D, Andren AC, Owen JH, Rau S, Su F, Cao X, Parolia A, Prince M, Fry J, Gardner PA, Yang R, Judkins AR, Koschmann CJ, Venteicher AS, Lyssiotis CA, Chinnaiyan AM, Venneti S.   +24 more
europepmc   +1 more source

Differentiation Syndrome and Sweet Syndrome‐Like Overlap Following Venetoclax–Azacytidine and G‐CSF Therapy

JEADV Clinical Practice, Volume 5, Issue 3, Page 967-970, September 2026.
ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki, Maria Gerbesi, Zoe Apalla, Dimitrios Tsokanas, Efstathia Pasmatzi, Alexandros Spyridonidis, Maria Liga   +6 more
wiley   +1 more source

Preoperative assessment of intratumor heterogeneity using intravoxel incoherent motion MRI for survival prediction in high-grade gliomas: a feasibility study. [PDF]

BMC Med Imaging
Wang X, Wang Y, Wang X, Liu F, Suo S, Song Y, Zhou Y, Cao M.   +7 more
europepmc   +1 more source

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

MedComm, Volume 7, Issue 9, September 2026.
Tumor metabolic reprogramming converges on three hubs—the SREBP1/2–FASN–SCD1 lipogenic axis, the HIF‐1α–GLUT1–LDHA glycolytic axis, and the LDLR–SCARB1–LXR cholesterol system—which integrate transcriptional, epigenetic (histone lactylation, m6A), and microenvironmental inputs to generate metabolic plasticity, immune evasion, and therapy resistance ...
Jia‐Chen Cheng, Yi‐Xuan Hu, Xiang‐Chun Huang, Shan Jiang, Jie‐Lin Wang, Yang Zhao, Shuo Chen   +6 more
wiley   +1 more source

Clinical advancement in the management of mutant isocitrate dehydrogenase (<i>IDH</i>) cancers. [PDF]

EJC Suppl
Bridgewater J, Tabatabai G, Macarulla T, Stacchiotti S.   +3 more
europepmc   +1 more source

Isocitrate Dehydrogenase (IDH) Mutations in Hematological Malignancies: Epidemiology, Mechanisms, and Therapeutic Strategies

MedComm – Future Medicine, Volume 5, Issue 3, September 2026.
IDH mutation is an important event in hematological malignancies. This review systematically integrates the basic mechanism of IDH mutations and combines it with the clinical translation of related research progress. It also discusses the application strategies of IDH inhibitors and feasible research directions, with the aim of providing a theoretical ...
Jinkun Xu, Haiying Bai, Lijuan Hu
wiley   +1 more source

Corrigendum to: The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. [PDF]

Neuro Oncol
europepmc   +1 more source

Isocitrate dehydrogenase mutations as potential tumour agnostic targets. [PDF]

EJC Suppl
Macarulla T, Tabatabai G, Stacchiotti S, Bridgewater J.   +3 more
europepmc   +1 more source

Nitric Oxide in Cancer: Mechanisms, Dual Role, and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Nitric oxide exerts concentration‐dependent dual roles in cancer, functioning as either a tumor promoter or suppressor. This review comprehensively examines NO's multifaceted regulation of tumor biology, including S‐nitrosylation signaling, metabolic reprogramming, immunemodulation, and therapy resistance, and highlights emerging therapeutic strategies
Jia Shao, Honghua Zhang, Jingyu Chen, Ziyu Qian, Ning Zhang, Yihua Zhang, Hui Ye, Jianbing Wu, Zhangjian Huang   +8 more
wiley   +1 more source

IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. [PDF]

Eur Urol
Cavka L, Nandakumar S, Wu Q, Mehta NJ, Ozay ZI, Begum A, Kundra R, Shannon E, Nazari SS, Evans MG, Smith N, Elliott A, Samueli B, Fine SW, Chen JF, Kantoff PW, Velho PI, Wang H, Sanin DE, Van Allen EM, Agarwal N, Abida W, Lotan TL, Schultz N, Antonarakis ES, Sena LA.   +25 more
europepmc   +1 more source